Furthermore, our study demonstrates that the combination therapy with SRC‐1 inhibitor and PD‐L1 antibody is much superior to monotherapy with either one, representing a novel strategy to potentiate immunotherapy in CRC patients with high levels of SRC‐1. Here, SRC is linked to colorectal carcinoma.